Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma

Blood Cancer J. 2021 Oct 20;11(10):169. doi: 10.1038/s41408-021-00562-9.

Cyrille Hulin^{1

2}, Meral Beksac³, Hugh J Goodman⁴, Ivan Spicka⁵, Adrian Alegre⁶, Miles Prince⁷, Frank Campana^{8

9}, Greg Finn⁸, Solenn Le-Guennec¹⁰, Sandrine Macé¹⁰, Stéphane Muccio¹⁰, Alexandra Tavernier¹⁰, Marie-Claude Rouchon^{10

9}, Paul G Richardson⁹

¹ Department of Hematology, Hospital De Haut Leveque, University Hospital, Pessac, France. cyrille.hulin@chu-bordeaux.fr.
² Ankara University School of Medicine, Department of Hematology, Ankara, Turkey. cyrille.hulin@chu-bordeaux.fr.
³ Waikato Hospital, Hamilton, New Zealand.
⁴ First Faculty of Medicine, Charles University and General Hospital, First Department of Medicine, Department of Hematology, Prague, Czech Republic.
⁵ Hematology Service, University Hospital La Princesa, Madrid, Spain.
⁶ University of Melbourne, Epworth Healthcare, Melbourne, Australia.
⁷ Sanofi, Cambridge, Mass, USA.
⁸ Sanofi Oncology, Cambridge, MA, USA.
⁹ Sanofi, Montpellier, France.
¹⁰ Sanofi R&D, Vitry-sur-seine, France.

No abstract available

Publication types